AbZelectPRO™: Enhanced Cell Line Development Platform Poster from BioProcess International East 2025

Our head of cell line development, Dr Brett Verstak, recently presented a poster titled “AbZelectPRO™: Enhanced Cell Line Development Platform” at BioProcess International East 2025 in Boston, focused on the benefits of our newly enhanced cell line platform.  With additions including two GS Knockout cell lines (Revvity CHOSOURCE),  increased productivity, proven performance, and rapid timelines, the newly enhanced offering enables biopharma customers to progress from DNA to RCB with flexbility and ease.

Abstract

Our fully integrated AbZelectPRO platform enables the rapid delivery of stable, high-producing cell lines for complex biologics or bioconjugates. AbZelectPRO combines our CHO-K1 mammalian cell line with ProteoNic’s 2G UNic® premium vector technology and a tailored optimised process to boost expression levels and generate faster doubling, higher-producing, stable cell lines, expressing up to 10 g/L of product.

As a result, the AbZelectPRO platform supports the efficient and stable production of antibodies and more difficult-to-express proteins such as fusion proteins, bi-specifics, vaccines and other novel modalities. Backed by the extensive experience of Abzena’s experts in developing biologic therapeutics, which are supported by Abzena’s comprehensive analytics portfolio, the AbZelectPRO platform simplifies the IND application process and delivers client therapeutic proteins successfully to clinical phases. In addition, the platform enables activities such as downstream method development and formulation to be removed from the CLD critical path by using Early Material Generation from Stable Pools, which can also be run stand-alone as part of the Abzena offer.

Click Here to Access the Poster